**About LScarisk.org**

This website is based on the following publications:

<a href="http://www.ncbi.nlm.nih.gov/pubmed/26657901" target="_blank">Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Sampson JR, Capella G, Mecklin JP, Möslein G; Mallorca Group (2017). <b>Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database</b>. <i>Gut</i> 2017 Mar;66(3):464-472.</a>

<a href="http://www.ncbi.nlm.nih.gov/pubmed/27261338" target="_blank">Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Möslein G, Sampson JR, Capella G; Mallorca Group (2016). <b>Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database</b>. <i>Gut</i> 2016 Jun 3</a>

<a href="http://www.ncbi.nlm.nih.gov/pubmed/28754778" target="_blank">Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons RH, Jeffries J, Vasen HFA, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen JT, Jenkins MA, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Valentin MD, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Möslein G, Sampson JR, Capella G; Mallorca Group (2017). <b>Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database</b>. <i>Gut</i> 2017 Jul 28</a>


Note that the number of PMS2 carriers included are insufficient for realiable conclusions. Risk estimates for PMS2 carriers should therefore be interpreted with caution. 

<!--Due to the low penetrance of MSH6 before 50 years of age, few MSH6 carriers with cancer before 50 years of age were included. Calculated results on next cancer in patients of age less than 50 years should thus not be considered for MSH6 carriers.-->


The information contained in this website is for general information purposes only. We make no representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, for interpretation or use in clinical practice, or otherwise contained on the website for any purpose.

Any reliance you place on such information is therefore strictly at your own risk. In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

See [InSIGHT](http://www.insight-group.org) and [European Hereditary Tumour group](http://www.mallorca-group.org) (formerly the Mallorca Group) for further information.

Editors: Sigve Nakken, Eivind Hovig, & Pål Møller

Contact: moller.pal@gmail.com

